Sarepta Therapeutics (SRPT) Other Gross PP&E Adjustments: 2011-2025
Historic Other Gross PP&E Adjustments for Sarepta Therapeutics (SRPT) over the last 12 years, with Sep 2025 value amounting to -$158.0 million.
- Sarepta Therapeutics' Other Gross PP&E Adjustments fell 12.13% to -$158.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year increase of 36.46%. This contributed to the annual value of $408.5 million for FY2024, which is 50.74% up from last year.
- Per Sarepta Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$158.0 million for Q3 2025, which was up 6.87% from -$169.7 million recorded in Q2 2025.
- Sarepta Therapeutics' 5-year Other Gross PP&E Adjustments high stood at $408.5 million for Q4 2024, and its period low was -$170.6 million during Q1 2025.
- For the 3-year period, Sarepta Therapeutics' Other Gross PP&E Adjustments averaged around -$56.7 million, with its median value being -$147.3 million (2024).
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first surged by 51.32% in 2021, then tumbled by 176.70% in 2023.
- Over the past 5 years, Sarepta Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $248.9 million in 2021, then rose by 1.21% to $251.9 million in 2022, then climbed by 7.58% to $271.0 million in 2023, then soared by 50.74% to $408.5 million in 2024, then decreased by 12.13% to -$158.0 million in 2025.
- Its Other Gross PP&E Adjustments stands at -$158.0 million for Q3 2025, versus -$169.7 million for Q2 2025 and -$170.6 million for Q1 2025.